Results 1 to 10 of about 662,171 (199)

Drug-induced tardive dyskinesia

Неврология, нейропсихиатрия, психосоматика, 2020
Tardive dyskinesia (TD) is a type caused by the use of different medications. The pathogenesis of TD is associated with dopamine receptor blockade, gamma-aminobutyric acid depletion, cholinergic deficiency, oxidative stress, impaired synaptic plasticity,
T. M. Ostroumova, V. A. Tolmacheva, O. D. Ostroumova, V. A. Parfenov   +3 more
doaj   +3 more sources

New insights into the mechanism of drug-induced dyskinesia

CNS Spectrums, 2012
Dyskinesia is an extrapyramidal movement disorder characterized by involuntary, repetitive, irregular motions that affect the mouth and face and/or the limbs and trunk. Tardive dyskinesia (TD) is a well-known complication of long-term treatment with antipsychotic drugs.
Loonen, Anton J. M., Ivanova, Svetlana A.   +1 more
openaire   +3 more sources

Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia

Frontiers in Aging Neuroscience, 2020
Levodopa (L-DOPA) treatment is the main gold-standard therapy for Parkinson disease (PD). Besides good antiparkinsonian effects, prolonged use of this drug is associated to the development of involuntary movements known as L-DOPA-induced dyskinesia (LID).
Valeria Calabrese, Valeria Calabrese, Anna Di Maio, Gioia Marino, Gioia Marino, Antonella Cardinale, Antonella Cardinale, Giuseppina Natale, Giuseppina Natale, Arianna De Rosa, Federica Campanelli, Federica Campanelli, Maria Mancini, Francesco Napolitano, Francesco Napolitano, Luigi Avallone, Paolo Calabresi, Paolo Calabresi, Alessandro Usiello, Alessandro Usiello, Veronica Ghiglieri, Veronica Ghiglieri, Barbara Picconi, Barbara Picconi   +23 more
doaj   +2 more sources

Drug-induced dyskinesia when taking Fluvoxamine

Неврология, нейропсихиатрия, психосоматика
Drug-induced movement disorders (DIMD) are a significant problem in clinical practice, especially in the context of the use of psychotropic drugs.
A. A. Katok, D. M. Khasanova, I. A. Khasanov   +2 more
doaj   +2 more sources

Letter: Clonazepam in the treatment of drug-induced dyskinesia. [PDF]

BMJ, 1975
P. O'Flanagan
openaire   +3 more sources

Transcranial Magnetic Stimulation Alleviates Levodopa-Induced Dyskinesia in Parkinson's Disease and the Related Mechanisms: A Mini-Review

Frontiers in Neurology, 2021
After long-term use of levodopa, Parkinson's patients almost inevitably develop dyskinesia, a kind of drug side effect manifesting as uncontrollable choreic movements and dystonia, which could be crippling yet have limited therapeutic options ...
Yi Wu, Xue-bing Cao, Wei-qi Zeng, Heng Zhai, Xiao-qian Zhang, Xiao-man Yang, Chi Cheng, Jia-ling Wang, Xiao-mei Yang, Yan Xu   +9 more
doaj   +1 more source

Phenytoin-induced dyskinesia: a case report

Journal of Medical Case Reports, 2023
Background Dyskinesia is a movement disorder categorized by involuntary movement of muscle. Although dyskinesia can be brought on by taking medications, it can also be a symptom of a variety of diseases.
Kashvi C. Shah, Nishi S. Patel, Paritosh Vasani, Avinash Khadela, Vivek P. Chavda, Lalitkumar Vora   +5 more
doaj   +1 more source

Levodopa-induced dyskinesia: A historical review of Parkinson’s disease, dopamine, and modern advancements in research and treatment

Journal of Neurology, 2022
Over the past two decades, animal models of Parkinson’s disease (PD) have helped to determine the plausible underlying mechanism of levo-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia following l-DOPA treatment.
Carissa A. Hansen, Douglas R. Miller, Stephanie Annarumma, C. Rusch, A. Ramirez-Zamora, H. Khoshbouei   +5 more
semanticscholar   +1 more source

Adaptive gene regulation in the Striatum of RGS9-deficient mice. [PDF]

PLoS ONE, 2014
BACKGROUND: RGS9-deficient mice show drug-induced dyskinesia but normal locomotor activity under unchallenged conditions. RESULTS: Genes related to Ca2+ signaling and their functions were regulated in RGS9-deficient mice.
Kathy Busse, Rainer Strotmann, Karl Strecker, Florian Wegner, Vasudharani Devanathan, Antje Gohla, Torsten Schöneberg, Johannes Schwarz   +7 more
doaj   +1 more source

Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia

Journal of Experimental Pharmacology, 2021
L-dopa-induced dyskinesia (LID) is the most frequent motor complication associated with chronic L-dopa treatment in Parkinson’s disease (PD). Recent advances in the understanding of the pathophysiological mechanisms underlying LID suggest that ...
A. Fabbrini, A. Guerra
semanticscholar   +1 more source